Literature DB >> 16778460

'Keratolytic' properties of benzoyl peroxide and retinoic acid resemble salicylic acid in man.

J M Waller1, F Dreher, S Behnam, C Ford, C Lee, T Tiet, G D Weinstein, H I Maibach.   

Abstract

OBJECTIVES: Retinoic acid (RA) and benzoyl peroxide (BP) were studied, comparing their keratolytic efficacy and water barrier disruption to that of salicylic acid (SA), a well-established keratolytic, under similar conditions. PATIENTS/
METHODS: Six volunteers were included in this blinded study. Eleven randomized test sites were marked on the volar forearms, containing sites for untreated skin at time zero, unoccluded, occlusion, and vehicle controls for 3 and 6 h, and each of BP, RA, and SA solutions for 3 and 6 h. At each time point, occlusion at 5 of the test sites was removed, and chromameter measurements were performed over 30 min. Each site then underwent 25 stratum corneum (SC) tape strippings. At 1, 5, and 30 min after the last stripping at each site, TEWL measurements were performed. Quantitative protein analysis of the SC from the tapes was then performed. RESULTS AND
CONCLUSION: after 3 h, bp was significantly more effective in disrupting sc cohesion than sa and ra, indicating bp is a moderate keratolytic agent in addition to its antimicrobial properties. After 6 h, all three agents were similarly effective in keratolysis. Barrier disruption, as measured by TEWL, paralleled depth of SC removal. SA tended to exhibit the greatest keratolytic efficacy superficially, hence its clinical effectiveness in superficial conditions such as comedonal acne, whereas BP was more effective at deeper levels, complimenting its antimicrobial effects and enabling it to treat deeper, more inflammatory lesions. None of the agents significantly affected skin erythema. These techniques provide a robust and rapid assay for in vivo keratolytic demonstration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16778460     DOI: 10.1159/000093984

Source DB:  PubMed          Journal:  Skin Pharmacol Physiol        ISSN: 1660-5527            Impact factor:   3.479


  8 in total

1.  Synergy and its clinical reievance in topical acne therapy.

Authors:  Leon H Kircik
Journal:  J Clin Aesthet Dermatol       Date:  2011-11

2.  A New, Once-daily, Optimized, Fixed Combination of Clindamycin Phosphate 1.2% and Low-concentration Benzoyl Peroxide 2.5% Gel for the Treatment of Moderate-to-Severe Acne.

Authors:  Michael H Gold
Journal:  J Clin Aesthet Dermatol       Date:  2009-05

3.  A Meta-analysis to Investigate the Relation Between Fitzpatrick Skin Types and Tolerability of Adapalene-Benzoyl Peroxide Topical Gel in Subjects with Mild or Moderate Acne.

Authors:  Valerie D Callender; Norman Preston; Cris Osborn; Lori Johnson; Ronald W Gottschalk
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

4.  In-vivo Effectiveness of Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel on Antibiotic-sensitive and Resistant Propionibacterium acnes.

Authors:  James J Leyden; Norman Preston; Cris Osborn; Ronald W Gottschalk
Journal:  J Clin Aesthet Dermatol       Date:  2011-05

Review 5.  Clinical efficacy and safety of benzoyl peroxide for acne vulgaris: Comparison between Japanese and Western patients.

Authors:  Makoto Kawashima; Toshitaka Nagare; Masaharu Doi
Journal:  J Dermatol       Date:  2017-08-09       Impact factor: 4.005

Review 6.  p53: key conductor of all anti-acne therapies.

Authors:  Bodo C Melnik
Journal:  J Transl Med       Date:  2017-09-19       Impact factor: 5.531

Review 7.  Peroxides with Anthelmintic, Antiprotozoal, Fungicidal and Antiviral Bioactivity: Properties, Synthesis and Reactions.

Authors:  Vera A Vil'; Ivan A Yaremenko; Alexey I Ilovaisky; Alexander O Terent'ev
Journal:  Molecules       Date:  2017-11-02       Impact factor: 4.411

Review 8.  Profile of clindamycin phosphate 1.2%/benzoyl peroxide 3.75% aqueous gel for the treatment of acne vulgaris.

Authors:  Tuyet A Nguyen; Lawrence F Eichenfield
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-10-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.